Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study
Cardiovasc Diabetol. 2026 May 14. doi: 10.1186/s12933-026-03209-w. Online ahead of print.ABSTRACTBACKGROUND AND AIMS: Reducing plasma levels of low-density lipoprotein cholesterol (LDL-C) is the cornerstone in the prevention of coronary artery disease (CAD) but may also increase risk of type 2 diabe

